Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Optimal Stent Deployment Strategy of Contemporary Stents
The primary objective is to evaluate whether a standard pre- and postdilatation (PSP strategy) of the modern DES results in a more optimal stent implantation compared to DS as evaluated by OCT in patients with stable coronary…
- Trial name
- PERFECTPSP (NCT05292651)
- Testing
- PCI
- Where
- Netherlands
- Volunteers
- 248 people
- Sponsor
- Albert Schweitzer Hospital
Coronary Artery Disease, Acute Coronary Syndrome
Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial
We hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after PCI in patients with acute coronary syndrome(ACS).
- Trial name
- NCT03797651
- Testing
- Standard DAPT, Very-short DAPT less than 1 month after PCI
- Where
- South Korea
- Volunteers
- 2,850 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Ischemic Heart Disease
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
- Trial name
- ECLIPSE (NCT03108456)
- Testing
- Orbital Atherectomy, Balloon
- Where
- 104 sites in United States
- Volunteers
- 2,005 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent
Restenosis due to neointimal hyperplasia causes repeat target vessel revascularization in a relevant number of patients undergoing percutaneous coronary interventions (PCI).
- Trial name
- IN-PACT CORO (NCT01057563)
- Testing
- drug (paclitaxel)-eluting balloon (DEB), bare-metal stent (BMS)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Catholic University of the Sacred Heart
Coronary Artery Disease, Percutaneous Coronary Intervention
Study on the Preferences for PCI Implantation Devices Among Doctors and Patients
The contemporary percutaneous treatment of coronary artery disease typically involves initial lesion preparation with balloon angioplasty, followed by the deployment of a drug-eluting stent (DES) to provide an immediate scaffold…
- Trial name
- REC-DEVICEPREF (NCT07378163)
- Testing
- Questionnaire
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Xijing Hospital
Coronary Artery Disease
The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)
The purpose of this study is to assess the safety and effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by…
- Trial name
- NCT01665053
- Testing
- PROMUS Element Plus, SYNERGY
- Where
- 126 sites in United States, Australia and 14 more
- Volunteers
- 1,684 people
- Sponsor
- Boston Scientific Corporation
Myocardial Infarction
Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients
The trial has the following primary objective: To compare the safety and effectiveness of primary acute MI intervention with ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs.
- Trial name
- ZEST-AMI (NCT00422565)
- Testing
- Endeavor, Medtronic, Cypher, Cordis, Taxus Liberte, Boston Scientific
- Where
- 12 sites in South Korea
- Volunteers
- 328 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease
The Real-World Drug-Coated Balloon Registry (RW-DCB) is an investigator-initiated, multicenter, observational cohort study evaluating the use of drug-coated balloons (DCBs) during percutaneous coronary intervention (PCI) in…
- Trial name
- RW-DCB (NCT07875088)
- Testing
- Coronary Drug-Coated Balloon
- Where
- 5 sites in Mexico, Spain
- Volunteers
- 2,000 people
- Sponsor
- Kristian Rivera
Coronary Artery Disease
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
This randomized study is a multi-center, randomized, study to compare the efficacy of biolimus A9-eluting stent (Nobori) vs. everolimus-eluting stent (Promus Element) for long coronary lesions.
- Trial name
- LONG-DES-V (NCT01186120)
- Testing
- Biolimus A9-eluting stent, Everolimus-eluting stent
- Where
- 11 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.
- Trial name
- NCT02520180
- Testing
- Firehawk™ stent system, Abbott Xience family Everolimus-Eluting Stent
- Where
- Denmark
- Volunteers
- 1,653 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent
This prospective, multicentre, open labeled, single arm, first in man interventional investigation aims to evaluate the safety of the ART18Z bioresorbable stent for the treatment of patients with single de novo lesion of a native…
- Trial name
- NCT01761578
- Testing
- ART18Z Bioresorbable stent
- Where
- 5 sites in France
- Volunteers
- 30 people
- Sponsor
- Arterial Remodeling Technologies
Coronary Artery Disease, Coronary Restenosis
The SCRIPPS DES REAL WORLD Registry
This study is a prospective, non-randomized, open-label registry of consecutive patients with CAD treated by stent-assisted PCI using at least one CypherTM stent. Up to 1000 pts will be included in the registry.
- Conditions
- Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
- Trial name
- NCT00714623
- Testing
- Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
- Where
- United States
- Volunteers
- 859 people
- Sponsor
- Paul S Teirstein, MD
Coronary Artery Disease
A Study to Examine the Implantation Characteristics of Two Drug-Eluting Stents
Despite recent advances in stent technology and clot reducing drug therapy, acute stent occlusion or thrombosis (ST), still occurs and can be life threatening.
- Trial name
- ORCA-2 (NCT01201369)
- Testing
- Coronary Stent Cypher, Coronary stent Xience
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Percutaneous Transluminal Coronary Angioplasty
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
The purpose of this study is to determine whether ABSORB bioresorbable vascular scaffold is non-inferior to XIENCE everolimus-eluting cobalt-chromium stent with respect to target-lesion failure (TLF) at 1 year.
- Trial name
- ABSORB-LONG (NCT02831205)
- Testing
- everolimus-eluting bioresorbable vascular (Absorb) scaffold, everolimus-eluting cobalt-chromium (Xience) stent
- Where
- South Korea
- Volunteers
- 800 people
- Sponsor
- Duk-Woo Park, MD
Chronic Coronary Occlusion, Vascular Disease
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
XIENCE V USA is a prospective, multi-center, multi-cohort post-approval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Coronary Occlusion, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-LTF (NCT01120379)
- Testing
- XIENCE V® EECSS
- Where
- United States
- Volunteers
- 5,034 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Everolimus- Versus Biolimus-Eluting Stents in All-Comers
This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer through 3 years of follow-up.
- Trial name
- EverBio (NCT01472705)
- Where
- Switzerland
- Volunteers
- 814 people
- Sponsor
- University of Freiburg
Coronary Disease
Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent
The purpose of this trial is to assess the safety and efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the treatment of single de novo bifurcation lesions in native coronary arteries with a main branch…
- Trial name
- BIPAX (NCT01308229)
- Testing
- Nile PAX® paclitaxel-eluting coronary stent
- Where
- 10 sites in Brazil, Bulgaria and 5 more
- Volunteers
- 102 people
- Sponsor
- MINVASYS
Hypertension, Coronary Artery Disease
Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was…
- Trial name
- NCT00139386
- Testing
- Candesartan
- Where
- Japan
- Volunteers
- 1,119 people
- Sponsor
- Kumamoto University
Coronary Artery Disease (non-left Main), Coronary Bifurcation Lesion
The European Bifurcation Club Randomized Trial of Stepwise Provisional Stenting Versus Drug Coated Balloon Therapy for Non-left Main True Coronary Bifurcations
Clinical outcomes are worse in patients with coronary artery bifurcation lesions, even if commonly encountered in clinical practice.
- Trial name
- EBC DCB (NCT06822322)
- Testing
- Percutaneous Coronary Angioplasty, Stepwise Provisional Stent Strategy, Drug Coated Balloon Strategy
- Volunteers
- 750 people
- Sponsor
- Ceric Sàrl
Coronary Artery Disease, Cardiovascular Diseases
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population
The primary objective of the RESOLUTE international registry is to document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a 'real-world' patient population requiring…
- Trial name
- R-Int (NCT00752128)
- Testing
- Endeavor Resolute Zotarolimus-Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 2,349 people
- Sponsor
- Medtronic Vascular